Ireland· IE-PA-EU/1/09/545/1-10
Onglyza 5 mg film-coated tablets
A saxagliptin product containing saxagliptin, registered in Ireland by AstraZeneca AB. The same ATC class is registered in 16 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Saxagliptin is registered in 16 of 19 countries.
Countries holding a registration under ATC A10BH03 (saxagliptin), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 10 of them publish a price we can compare per daily dose
Saxagliptin · ATC A10BH03
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of saxagliptin costs, country by country.
Normalised to the WHO defined daily dose (5 mg), the median price runs from $0.31 in France to $3.59 in Italy — a ×12 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Saxagliptin · price per daily dose (5 mg)
USD · FX 28 Sept 2026
- IT Italy$3.59
- CH Switzerland$3.41
- FR France$0.31
The record
At a glance
HPRA (Ireland)- Active substance
- Saxagliptin
- Manufacturer
- AstraZeneca AB
- Country
- Ireland (IE)
- ATC code
- A10BH03
- ATC class
- Saxagliptin
- Defined daily dose
- 5 mg, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/09/545/1-10
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
449 interactions on record for saxagliptin.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Saxagliptin · interactions on record
449 records
- 3 severe
- 404 moderate
- 42 minor
Most severe, free to view
- ClotrimazoleA01AB18moderate
- CimetidineA02BA01moderate
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Saxagliptin in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaONGLYZAAstraZeneca AB, Södertälje
- SpainONGLYZA 5 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAstrazeneca Ab
- BelgiumOnglyza 5 mgAstraZeneca
- FranceONGLYZA 5 mg, comprimé pelliculéASTRAZENECA AB
- United StatesSaxagliptinAurobindo Pharma Limited
- NetherlandsOnglyza 5 mg, filmomhulde tablettenAstraZeneca AB
- IcelandOnglyzaAstraZeneca AB
- NorwayOnglyzaOrifarm AS
Authorised across Europe · EMA
The same active substance is authorised in 9 EEA countries. Names it is sold under:
- France · Saxagliptine Arrow, Saxagliptine Biogaran
- United Kingdom (Northern Ireland) · Saxagliptin Sandoz, Saxagliptin Zydus Pharmaceuticals Uk
- Hungary · Saxagliptin Pharos
- Iceland · Onglyza
- Liechtenstein · Onglyza
- Malta · Saxagliptin Pharos
- Netherlands · Saxagliptine Sandoz
- Norway · Onglyza
- Portugal · Saxagliptina Generis, Saxagliptina Generis Phar
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e599002c-35ee-4f90-ab9f-61066d2ccad7 GET /v1/drugs/e599002c-35ee-4f90-ab9f-61066d2ccad7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"A10BH",
"A10BH03"
],
"strength": null,
"pa_number": "EU/1/09/545/1-10",
"substances": [
"Saxagliptin"
],
"legal_basis": "New active substance (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "01/10/2009",
"dispensing_status": "Product subject to prescription which may be renewed (B)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about saxagliptin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.